文献速递血栓与止血

体外整体凝血检测揭示NXT007存在下血友病A联合止血药物可能剂量的启示

Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A.
PubMed 文献 · J Thromb Haemost · 2025-04-06

本研究采用凝血酶生成试验、凝块波形分析和旋转血栓弹力测量,在加入NXT007的血友病A血浆和全血样本中观察重组FVIII、重组FVIIa和活化凝血酶原复合物的体外效应。单剂NXT007≥10.0 μg/mL(血浆)即可达到非血友病凝血潜力;NXT007 15.0 μg/mL(全血)联合APCC 0.13 U/mL(相当于10.0 U/kg后即刻血药水平)的旋转血栓弹力参数与临床浓度艾米珠单抗联合APCC 0.63 U/mL(相当于推荐初始剂量50.0 U/kg后即刻水平)相当。

要点

  • 单剂NXT007≥10.0 μg/mL(血浆)在体外达到非血友病凝血潜力。
  • NXT007 0.1至50.0 μg/mL时,联用rFVIII、rFVIIa或APCC均增强多项凝血参数。
  • NXT007 15.0 μg/mL联合APCC 0.13 U/mL的旋转血栓弹力参数与艾米珠单抗联合APCC 0.63 U/mL相当。

核心结论

  • 体外联合加入凝血药物可在NXT007存在下提高凝血潜力。
  • 当探索在血浆NXT007水平约30.0 μg/mL时联用APCC,10.0 U/kg的剂量或可作为初始剂量的粗略参考指标。
  • 血浆NXT007≥10.0 μg/mL在体外显示非血友病凝血潜力。

研究设计与样本

  • 体外研究,采用凝血酶生成试验、凝块波形分析和旋转血栓弹力测量,使用加入NXT007等的血友病A血浆和全血样本。

主要发现

  • 单剂NXT007≥10.0 μg/mL(血浆)达到非血友病凝血潜力。
  • 在NXT007 0.1至50.0 μg/mL水平下,联合加入rFVIII、rFVIIa和APCC各自增强多项参数。
  • NXT007 15.0 μg/mL(全血)与APCC 0.13 U/mL(相当于10.0 U/kg给药后即刻血药水平)共存时,旋转血栓弹力参数与临床艾米珠单抗水平联合APCC 0.63 U/mL(相当于推荐初始剂量50.0 U/kg给药后即刻血药水平)时观察到的参数相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concomitant administration of activated prothrombin complex concentrate (APCC) at doses >100 U/kg/d is associated with thrombotic risk under emicizumab prophylaxis. In vitro global assay data on the effects of concomitant coagulation factor agents in the presence of NXT007, an emicizumab-based engineered bispecific antibody under clinical development, may serve as a basis for addressing this potential risk. OBJECTIVES: This study aimed to investigate the in vitro effects of recombinant factor (rF)VIII, rFVIIa, and APCC during NXT007 treatment and estimate tolerable doses with reference to emicizumab. METHODS: Thrombin generation assays, clot waveform analysis, and rotational thromboelastometry were performed using hemophilia A plasma and blood samples spiked with NXT007 and others. RESULTS: A single dose of NXT007 at ≥10.0 μg/mL (plasma) achieved a nonhemophiliac coagulation potential. The concomitant addition of rFVIII, rFVIIa, and APCC each boosted various parameters following NXT007 levels at 0.1 to 50.0 μg/mL. In the copresence of NXT007 at 15.0 μg/mL (blood) and APCC at 0.13 U/mL, with the blood level immediately following the administration of 10.0 U/kg, the rotational thromboelastometry parameters were comparable with those observed with clinical emicizumab level and APCC at 0.63 U/mL, corresponding to the blood level immediately after administrating 50.0 U/kg (recommended initial dose). CONCLUSION: Concomitant addition of coagulation agents increased coagulation potentials in vitro in the presence of NXT007. A dose of 10.0 U/kg may serve as a rough indicator for the initial dose when exploring the concomitant use of APCC at plasma NXT007 levels of ∼30.0 μg/mL. Importantly, plasma NXT007 at ≥10.0 μg/mL demonstrated non-hemophiliac coagulation potentials in vitro.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ogiwara K, Furukawa S, Inaba K, et al. Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A. J Thromb Haemost. 2025. PMID: 40199443. doi:10.1016/j.jtha.2025.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。